In accordance with most studies, we propose to define disease control as follows: prolactin normalization while using DAs without typical prolactinoma-related symptoms [ie, galactorrhea, loss of libido, subfertility, menstrual cycle disturbances, or erectile dysfunction (11)]. The gene discussed is PRL; the disease is Galactorrhea.